Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)
Status:
Terminated
Trial end date:
2009-09-01
Target enrollment:
0
Participant gender:
All
Summary
This is a Phase II randomized, double-masked study comparing the safety and efficacy of
ATG003 (mecamylamine HCl) 1.0% and 0.3% ophthalmic solutions to placebo in patients with
neovascular ("wet") age-related macular degeneration (NV-AMD).